King’s College London, London. United Kingdom
Understanding unique health needs to inform personalised treatment: multimorbidity and clusters of long-term health conditions in people with Down syndrome compared to the general population and people with other intellectual disabilities
Research Foundation for Mental Hygiene Inc. at the Nathan S. Kline Institute for Psychiatric Research. New York. United States
Elucidating the role of mitovesicles, newly identified extracellular vesicles of mitochondrial origin, in the propagation of mitochondrial dysfunction in Down syndrome
University of Alabama at Birmingham. Unites States
HMGN1 as a Mediator of Dysregulated Sonic Hedgehog Signalling and Autism Risk in Down Syndrome
Scuola Normale Superiore, Pisa. Italy
Microglial cells as contributors to the excitatory/inhibitory balance: a key to understanding epileptic prevalence in Down Syndrome
Institut du Fer à Moulin. Paris, France
Primary cilium-dependent cortical interneuron migration in Down Syndrome mouse models
Institut du Cerveau et de la Moelle Epinière. Paris, France
Elucidating the effects of age-related and tissue-specific modulation of DYRK1A expression on Alzheimer’s disease-like pathology in mice
Centre for Genomic Regulation. Barcelona, Spain
Stratifying Cognitive Improvements to Reveal the Effect of Allelic Diversity in Trisomy 21
Monash University. Clayton, Australia
Understanding how gene interactions in Down syndrome impacts cognitive decline; structure to function relationships in brains
University of Naples Federico II. Naples, Italy
Defects in mitophagy and mitochondrial activity as key determinants of Alzheimer’s disease in Down Syndrome: novel therapeutic strategies
Fondazione Istituto Italiano di Tecnologia. Genova, Italy
Early NKCC1 Inhibition to treat epilepsy and hyperactivity in Down syndrome
KU Leuven. Leuven, Belgium
Cardiopulmonary-vascular disorders in Down syndrome research: a long-overlooked issue
University of Queensland. Brisbane, Australia
Elucidating the genetic drivers of accelerated cellular ageing in Down syndrome
University of Western Australia. Perth, Australia
Down syndrome-Acute lymphoblastic leukaemia (DS-ALL): A model to unravel the molecular mechanisms underlying treatment-resistance in paediatric leukaemia »
*Co-financed by Fondation Sisley-D’Ornano
Blizzard Institute. Queen Mary University of London. London, United Kingdom
Assessment of specific biological features of trisomy 21 neurons, affecting cell-cell transmission of Alzheimer’s pathology using cerebral organoids
Institut du Cerveau et de la Moelle Epinière. Paris, France
Role of PFC SST+ interneurons on emotional state recognition in a mouse model of Down syndrome
Institut du Cerveau et de la Moelle Epinière. Paris, France
Uncovering the signaling pathways to neurodegeneration of the locus coerulus, and cognitive impairments in Down syndrome
*Co-financed by Fondation Sisley-D’Ornano
Stanford University. Stanford, United States
Usp16 as a new therapeutic target in Alzheimer disease and Down syndrome
Institut de Génétique et de Biologie Moléculaire et Cellulaire. Illkirch, France
Role of DYRK1A in GABAergic inhibitory neurons development, impact on the excitatory/inhibitory balance in diseases with intellectual disabilities
*Co-financed by Fondation Sisley-D’Ornano
Hospital de la Santa Creu i Sant Pau. Barcelona, Spain
Discovery of novel biomarkers signaling NGF metabolic dysfunction and early AD-dementia in Down syndrome
Life and health science research institute. University of Minho. Braga, Portugal
Tau therapeutics in Down syndrome & Alzheimer’s disease brain pathologies
*Co-financed by Fondation Sisley-D’Ornano